Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-Line Monotherapy Maintenance Treatment in Chinese Women with Platinum-Responsive Advanced Ovarian Cancer

NEXT STORY
Athenex to Host Key Opinion Leader Webinar on CAR-NKT Approach to Cancer
PREV STORY
OraSure Technologies Remains Committed to the Global Fight Against HIV 40 Years After the Discovery of the HIV Virus
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Preliminary Results from Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival in Combination with Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer

Patients on trilaciclib received more chemotherapy cycles than those in the control armTrilaciclib showed ...

author_avatar
NASDAQ Market News

New Novel Depicts the Life of a Modern-Day Everyman as He Navigates Anxiety, Disenchantment and Loss

author_avatar
NASDAQ Market News

American Botanical Council Presents Botanical Excellence Awards at 16th Annual Celebration Ceremony

author_avatar
NASDAQ Market News